en · de · es · pt
aod-9604-notes.peptides6608.com › Topic › Regulation And Detection Context — Common Mistakes

Regulation And Detection Context — Common Mistakes

By Editorial Desk · published 2025-07-30 · last reviewed 2025-08-24 · Topic

This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusProhibited in sportListed by WADA under peptide hormones
WADA classS2Peptide hormones, growth factors, related substances, and mimetics
Approved therapeutic useNot establishedClinical research did not lead to broad marketing approval
Common detection methodLC-MS/MSLiquid chromatography-tandem mass spectrometry
Sample preparationExtraction and enrichmentImmunoaffinity or solid-phase extraction may be used

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Related pages on this site

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Supporting material

=== 2016–present === In 2016, Quest collaborated with Safeway to bring testing services to twelve of its stores in California, Maryland, Virginia, Texas and Colorado. By the end of 2017, Quest, in partnership with Walmart, incorporated laboratory testing in about 15 of their locations in Texas and Florida. In May 2018, the company announced it will become an in-network laboratory provider to UnitedHealthcare starting in 2019, providing access to 48 million plan members. In September 2018, Quest moved its headquarters from Madison, where it was located since 2007, to Secaucus, New Jersey. In November 2018, Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing from home. In March 2020, the company launched a COVID-19 testing service. As of July 2020, Quest had performed more than 9.2 million COVID-19 molecular tests and 2.8 million serology tests. In April 2024, Quest has added a new blood screening to their AD-Detect product line. This test will analyze the blood for a specific Alzheimer's protein, pTau-217. In February 2025, Quest acquired select assets of Fresenius Medical Care's Spectra laboratories. Under a separate agreement, Quest now offers clinical testing and lab services related to dialysis and end-stage kidney disease.

=== Canada === In Canada, methadone can be prescribed in office settings and then picked up by patients at their local pharmacies. Regulations for methadone are made at the provincial level in Canada in comparison to the United States where much of the regulations comes from a federal level. While these offices offer counseling services, they are not required in order to receive methadone treatment. This practice coupled with methadone being accessible at community pharmacies makes the treatment more accessible to communities. In 1972, Canada's Narcotics Control Act prohibited the prescription of methadone to patients which stood in effect until 1996 when regulation of methadone became decentralized. Prescribers were still required to receive a federal exemption to prescribe methadone until 2018, during a spike in opioid overdose deaths, when the federal government removed this previously needed authorization. Nurse practitioners are also allowed to prescribe methadone in Canada. There is encouraged communication between the prescriber and pharmacist overseeing the treatment. Methadone will be denied to patients that show up to pharmacies visibly intoxicated or sedated state. In addition to pharmacies, methadone can be dispensed in assisted living facilities, long-term care facilities, and jails/prisons.

Supraphysiological levels of dihydrotestosterone (DHT) occur with scrotal application of testosterone, whereas this does not occur with non-scrotal transdermal application. This is due to the high expression of 5α-reductase in scrotal skin. Estradiol levels are similar with scrotal versus non-scrotal application of transdermal testosterone. Low-dose transdermal testosterone patches in women have been found to result in testosterone levels of 64 ng/dL with 150 μg/day and 102 ng/dL with 300 μg/day. When testosterone is used transdermally in women or trans men, hair growth at the application sites can happen.

Sources: en.wikipedia.org

Supporting material

British Post Office scandal: Secretary of State for Justice Alex Chalk tells Parliament the UK government is giving "serious consideration" to introducing legislation to quash the convictions of the 700 or so sub post masters who were prosecuted as a result of the Horizon IT scandal. Former Post Office chief executive Paula Vennells announces that she will hand back her CBE after more than a million people signed a petition calling for her to do so. Liberal Democrat leader Ed Davey, who was Post Office minister during the scandal, comes under pressure to return his knighthood. 10 January British Post Office scandal: Prime Minister Rishi Sunak announces that emergency legislation will be brought through Parliament to "swiftly exonerate and compensate victims" of the Post Office scandal in England and Wales. First Minister of Scotland Humza Yousaf confirms those in Scotland convicted because of the scandal will also be cleared, and that he will work with the UK government to bring this about. Baroness Heather Hallett, chair of the UK COVID-19 Inquiry, confirms the inquiry will postpone the start of hearing evidence about the development of a vaccine as more time is needed to prepare for a separate investigation into the impact of COVID-19 on the NHS. Consequently, the vaccine evidence, which was due to begin being heard in Summer 2024 may not begin until after the next general election. HS2 Ltd releases a revised forecast for building the London to Birmingham leg of the High Speed 2 rail link, which is now estimated to total £65bn.

== Acquisitions == Bruker acquisitions include GE NMR Instruments (1992), Siemens AXS (1997), Nonius (2001), MacScience (2002), Vacuumschmelze Hanau (2003), Röntec (2005), SOCABIM (2005), PGT (2005), Keymaster (2006), Quantron (2006), JuWe (2008), SIS (2008), ACCEL (2009), Michrom Bioresources (2011), Skyscan (2012), Prairie Technologies (2013), Oncovision (Preclinical PET imaging business, 2016), Oxford Instruments Superconducting Technology (2016), Hysitron Inc. (2017), XGLab (2017), Luxendo (2017), JPK Instruments (2018), Alicona (2018), PMOD Technologies LLC (2019), Canopy Biosciences (2020), Optimal Group (2022), Neurescence Inc (2022), PhenomeX (2023), MIRO Analytical (majority 2023), NanoString Technologies assets (2024), and ELITechGroup (2024).

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. Of the 90 unique tyrosine kinase genes identified in the human genome, 58 encode receptor tyrosine kinase proteins. Receptor tyrosine kinases have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Mutations in receptor tyrosine kinases lead to activation of a series of signalling cascades which have numerous effects on protein expression. The receptors are generally activated by dimerization and substrate presentation. Receptor tyrosine kinases are part of the larger family of protein tyrosine kinases, encompassing the receptor tyrosine kinase proteins which contain a transmembrane domain, as well as the non-receptor tyrosine kinases which do not possess transmembrane domains.

Sources: en.wikipedia.org

Supporting material

The mechanism of action on a cellular level is not well understood. However, it has been shown that binding of different sugars to the glucose site affects the orientation of the aglycone in the access vestibule. So when the aglycone binds, it affects the entire inhibitor. Together, these mechanisms lead to a synergistic interaction. Therefore, variations in the structure of both the sugar and the aglycone are crucial for the pharmacophore of SGLT inhibitors. Dapagliflozin is an example of an SGLT-2 inhibitor; it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying blood sugar control and kidney function. The results are decreased kidney reabsorption of glucose, glucosuria effect increases with higher levels of glucose in the blood circulation. Therefore, dapagliflozin reduces the blood glucose concentration with a mechanism that is independent of insulin secretion and sensitivity, unlike many other antidiabetic medications. Functional pancreatic β-cells are not necessary for the activity of the medication, so it is convenient for patients with diminished β-cell function. Sodium and glucose are co-transported by the SGLT-2 protein into the tubular epithelial cells across the brush-border membrane of the proximal convoluted tubule. This happens because of the sodium gradient between the tubule and the cell, and therefore provides a secondary active transport of glucose.

==== Proteins are optimised for catalysis ==== Proteins are functional macromolecules responsible for catalysing the biochemical reactions that sustain life. Proteins carry out all functions of an organism, for example photosynthesis, neural function, vision, and movement. The single-stranded nature of protein molecules, together with their composition of 20 or more different amino acid building blocks, allows them to fold in to a vast number of different three-dimensional shapes, while providing binding pockets through which they can specifically interact with all manner of molecules. In addition, the chemical diversity of the different amino acids, together with different chemical environments afforded by local 3D structure, enables many proteins to act as enzymes, catalyzing a wide range of specific biochemical transformations within cells. In addition, proteins have evolved the ability to bind a wide range of cofactors and coenzymes, smaller molecules that can endow the protein with specific activities beyond those associated with the polypeptide chain alone.

The Bowery Mural is an outdoor exhibition space located on the corner of Houston Street and the Bowery, on a wall owned by Goldman Properties since 1984. Real estate developer Tony Goldman began the project with Jeffery Deitch and Deitch Projects in 2008. Goldman's goal was to use this wall to present the top contemporary artists from around the world, with an emphasis on artists who work on the streets. Seasonal murals have appeared on the wall curated and organized in collaboration with The Hole, NYC, an art gallery in SoHo run by former Deitch Projects directors Kathy Grayson and Meghan Coleman. The mural series was initiated from March to December 2008 with a tribute to Keith Haring’s noted 1982 Bowery mural. This was followed by a mural by the Brazilian twin-brother duo Os Gêmeos, which they dedicated to artist Dash Snow, who had recently died from a drug overdose; this was presented from July 2009 to March 2010. The next mural, by Shepard Fairey, was on exhibit from April through August 2010, and was followed by a mural by Barry McGee which celebrated the role of graffiti tagging in the history of New York City street art; it was on display from August to November 2010. This was followed by a tribute to Dash Snow by Irak, which ran from November 24–26, 2010. Other artists to have murals presented include the twins How & Nosm (2012), Crash (2013), Martha Cooper (2013), Revok and Pose (2013), Swoon (2014), and Maya Hayuk.

PRPP also plays an important role in pyrimidine ribonucleotide synthesis. During the fifth step of pyrimidine nucleotide synthesis, PRPP covalently links to orotate at the one-position carbon on the ribose unit. The reaction is catalyzed by orotate phosphoriboseyltransferase (PRPP transferase), yielding orotidine monophosphate (OMP).

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 banned in sport?

Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.

How is AOD-9604 detected?

Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.

Does AOD-9604 have approved therapeutic uses?

No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

Network